Via EDGAR Submission
States Securities and Exchange Commission
of Life Sciences100 F Street, N.E.
GT Biopharma, Inc.
Statement on Form S-1
Registration No. 333-251311
Pursuant to Rule
461 under the Securities Act of 1933, as amended (the
“Securities Act”), the undersigned, as underwriters of
the proposed offering, hereby joins the request of the Company that
the effective date of the above-referenced Registration Statement
on Form S-1 be declared effective at 5:00 PM Eastern Time on
February 10, 2021, or as soon as practicable
connection with this acceleration request and pursuant to Rule 460
under the Securities Act, please be advised that between February
8, 2021 and the date hereof, over 1,500 copies of the preliminary
prospectus dated February 9, 2021 were distributed to underwriters,
dealers, institutions and others.
undersigned advise that the underwriters have complied and will
continue to comply with Rule 15c2-8 under the Securities Exchange
Act of 1934, as amended.
you for your assistance with this matter.
Capital Partners, LLC
/s/ Aaron M.
Aaron M. Gurewitz
Head of Equity Capital Markets
James Securities, Inc.
/s/ Robert D. Keyser
Robert D. Keyser Jr.